{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T12:49:33Z","timestamp":1789735773161,"version":"4.0.1"},"reference-count":139,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2024,1,19]],"date-time":"2024-01-19T00:00:00Z","timestamp":1705622400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pharmacol."],"abstract":"<jats:p>In light of a global rise in the number of patients with type 2 diabetes mellitus (T2DM) and obesity, non-alcoholic fatty liver disease (NAFLD), now known as metabolic dysfunction-associated fatty liver disease (MAFLD) or metabolic dysfunction-associated steatotic liver disease (MASLD), has become the leading cause of hepatocellular carcinoma (HCC), with the annual occurrence of MASLD-driven HCC expected to increase by 45%\u2013130% by 2030. Although MASLD has become a serious major public health threat globally, the exact molecular mechanisms mediating MASLD-driven HCC remain an open problem, necessitating future investigation. Meanwhile, emerging studies are focusing on the utility of bioactive compounds to halt the progression of MASLD to MASLD-driven HCC. In this review, we first briefly review the recent progress of the possible mechanisms of pathogenesis and progression for MASLD-driven HCC. We then discuss the application of bioactive compounds to mitigate MASLD-driven HCC through different modulatory mechanisms encompassing anti-inflammatory, lipid metabolic, and gut microbial pathways, providing valuable information for future treatment and prevention of MASLD-driven HCC. Nonetheless, clinical research exploring the effectiveness of herbal medicines in the treatment of MASLD-driven HCC is still warranted.<\/jats:p>","DOI":"10.3389\/fphar.2023.1336216","type":"journal-article","created":{"date-parts":[[2024,1,18]],"date-time":"2024-01-18T23:49:31Z","timestamp":1705621771000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":24,"title":["Pharmacological therapy of metabolic dysfunction-associated steatotic liver disease-driven hepatocellular carcinoma"],"prefix":"10.3389","volume":"14","author":[{"given":"Yumin","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joshua S.","family":"Fleishman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tongda","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yulin","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhao","family":"Ren","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jichao","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mingchao","family":"Ding","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2024,1,19]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"174","DOI":"10.1016\/j.intimp.2017.01.016","article-title":"Curcumin ameliorates liver damage and progression of NASH in NASH-HCC mouse model possibly by modulating HMGB1-NF-\u03baB translocation","volume":"44","author":"Afrin","year":"2017","journal-title":"Int. Immunopharmacol."},{"key":"B2","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1038\/s41416-022-01998-x","article-title":"Ferroptosis in hepatocellular carcinoma: mechanisms and targeted therapy","volume":"128","author":"Ajoolabady","year":"2023","journal-title":"Br. J. Cancer."},{"key":"B3","doi-asserted-by":"publisher","first-page":"1683","DOI":"10.1001\/jamaoncol.2017.3055","article-title":"The burden of primary liver cancer and underlying etiologies from 1990 to 2015 at the global, regional, and national level: results from the global burden of disease study 2015","volume":"3","author":"Akinyemiju","year":"2017","journal-title":"JAMA Oncol."},{"key":"B4","doi-asserted-by":"publisher","first-page":"858","DOI":"10.1002\/hep.27016","article-title":"Inflammatory and metabolic biomarkers and risk of liver and biliary tract cancer","volume":"60","author":"Aleksandrova","year":"2014","journal-title":"Hepatology"},{"key":"B5","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1038\/s41575-019-0145-7","article-title":"From NASH to HCC: current concepts and future challenges","volume":"16","author":"Anstee","year":"2019","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"B6","doi-asserted-by":"publisher","first-page":"16206","DOI":"10.1038\/s41598-022-20296-3","article-title":"Probiotics suppress nonalcoholic steatohepatitis and carcinogenesis progression in hepatocyte-specific PTEN knockout mice","volume":"12","author":"Arai","year":"2022","journal-title":"Sci. Rep."},{"key":"B7","doi-asserted-by":"publisher","first-page":"1294","DOI":"10.1007\/s10620-016-4049-x","article-title":"Innate immunity and inflammation in NAFLD\/NASH","volume":"61","author":"Arrese","year":"2016","journal-title":"Dig. Dis. Sci."},{"key":"B8","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1016\/j.metabol.2018.11.001","article-title":"Obesity and cancer risk: emerging biological mechanisms and perspectives","volume":"92","author":"Avgerinos","year":"2019","journal-title":"Metab. Clin. Exp."},{"key":"B9","doi-asserted-by":"publisher","first-page":"1497","DOI":"10.1002\/hep.26226","article-title":"Mitochondrial adaptations and dysfunctions in nonalcoholic fatty liver disease","volume":"58","author":"Begriche","year":"2013","journal-title":"Hepatology"},{"key":"B10","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1038\/s41467-020-20422-7","article-title":"Gut microbiota impact on the peripheral immune response in non-alcoholic fatty liver disease related hepatocellular carcinoma","volume":"12","author":"Behary","year":"2021","journal-title":"Nat. Commun."},{"key":"B11","doi-asserted-by":"publisher","first-page":"50101143","DOI":"10.1016\/j.molmet.2020.101143","article-title":"Metabolic drivers of non-alcoholic fatty liver disease","volume":"50","author":"Bence","year":"2021","journal-title":"Mol. Metab."},{"key":"B12","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1007\/s00018-018-2947-0","article-title":"Molecular pathways of nonalcoholic fatty liver disease development and progression","volume":"76","author":"Bessone","year":"2019","journal-title":"Cell. Mol. Life Sci."},{"key":"B13","doi-asserted-by":"publisher","first-page":"5155","DOI":"10.1038\/s41388-021-01950-y","article-title":"Oxidative stress in obesity-associated hepatocellular carcinoma: sources, signaling and therapeutic challenges","volume":"40","author":"Brahma","year":"2021","journal-title":"Oncogene"},{"key":"B14","doi-asserted-by":"publisher","first-page":"BSR20221271","DOI":"10.1042\/BSR20221271","article-title":"Inflammatory processes involved in NASH-related hepatocellular carcinoma","volume":"43","author":"Cannito","year":"2023","journal-title":"Biosci. Rep."},{"key":"B15","doi-asserted-by":"publisher","first-page":"197","DOI":"10.7570\/jomes23052","article-title":"Metabolic dysfunction-associated steatotic liver disease (MASLD): a state-of-the-art review","volume":"32","author":"Chan","year":"2023","journal-title":"J. Obes. Metab. Syndr."},{"key":"B16","doi-asserted-by":"publisher","first-page":"174","DOI":"10.1016\/j.freeradbiomed.2020.06.011","article-title":"Corrigendum to \"Role of oxidative stress in the pathogenesis of nonalcoholic fatty liver disease\" [Free Radic. Biol. Med. 152 (2020) 116-141]","volume":"152","author":"Chen","year":"2020","journal-title":"Free Radic. Biol. Med."},{"key":"B17","doi-asserted-by":"publisher","first-page":"1090338","DOI":"10.3389\/fnut.2023.1090338","article-title":"Ferroptosis in non-alcoholic liver disease: molecular mechanisms and therapeutic implications","volume":"10","author":"Cheng","year":"2023","journal-title":"Front. Nutr."},{"key":"B18","doi-asserted-by":"publisher","first-page":"2157","DOI":"10.1097\/CM9.0000000000002327","article-title":"New perspectives on ferroptosis and its role in hepatocellular carcinoma","volume":"135","author":"Cong","year":"2022","journal-title":"Chin. Med. J."},{"key":"B19","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1016\/S2468-1253(16)30018-8","article-title":"Distinctive features of hepatocellular carcinoma in non-alcoholic fatty liver disease","volume":"1","author":"Degasperi","year":"2016","journal-title":"Lancet Gastroenterology Hepatology"},{"key":"B20","doi-asserted-by":"publisher","first-page":"3706","DOI":"10.3390\/foods12193706","article-title":"An update on the pivotal roles of probiotics, their components, and metabolites in preventing colon cancer","volume":"12","author":"Deng","year":"2023","journal-title":"Foods"},{"key":"B21","doi-asserted-by":"publisher","first-page":"710","DOI":"10.1016\/j.jhep.2018.11.034","article-title":"Metformin modulates innate immune-mediated inflammation and early progression of NAFLD-associated hepatocellular carcinoma in zebrafish","volume":"70","author":"de Oliveira","year":"2019","journal-title":"J. Hepatol."},{"key":"B22","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1002\/path.5871","article-title":"Oncostatin M is overexpressed in NASH-related hepatocellular carcinoma and promotes cancer cell invasiveness and angiogenesis","volume":"257","author":"Di Maira","year":"2022","journal-title":"J. Pathol."},{"key":"B23","doi-asserted-by":"publisher","first-page":"880298","DOI":"10.3389\/fimmu.2022.880298","article-title":"Association of inflammatory cytokines with non-alcoholic fatty liver disease","volume":"13","author":"Duan","year":"2022","journal-title":"Front. Immunol."},{"key":"B24","doi-asserted-by":"publisher","first-page":"1465","DOI":"10.1002\/2211-5463.13154","article-title":"Antitumor effects of low-dose tipifarnib on the mTOR signaling pathway and reactive oxygen species production in HIF-1\u03b1-expressing gastric cancer cells","volume":"11","author":"Egawa","year":"2021","journal-title":"FEBS Open Bio"},{"key":"B25","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1016\/j.jhep.2020.03.039","article-title":"A new definition for metabolic dysfunction-associated fatty liver disease: an international expert consensus statement","volume":"73","author":"Eslam","year":"","journal-title":"J. Hepatol."},{"key":"B26","doi-asserted-by":"publisher","first-page":"1999","DOI":"10.1053\/j.gastro.2019.11.312","article-title":"MAFLD: a consensus-driven proposed nomenclature for metabolic associated fatty liver disease","volume":"158","author":"Eslam","year":"","journal-title":"Gastroenterology"},{"key":"B27","doi-asserted-by":"publisher","first-page":"1496","DOI":"10.1111\/liv.15163","article-title":"Ferroptosis and metabolic dysfunction-associated fatty liver disease: is there a link","volume":"42","author":"Feng","year":"2022","journal-title":"Liver Int."},{"key":"B28","doi-asserted-by":"publisher","first-page":"446","DOI":"10.1016\/j.jhep.2021.09.007","article-title":"NAFLD-driven HCC: safety and efficacy of current and emerging treatment options","volume":"76","author":"Foerster","year":"2022","journal-title":"J. Hepatol."},{"key":"B29","doi-asserted-by":"publisher","first-page":"687","DOI":"10.3390\/biomedicines9060687","article-title":"The role of oxidative stress in NAFLD-NASH-HCC transition-focus on NADPH oxidases","volume":"9","author":"Gabbia","year":"2021","journal-title":"Biomedicines"},{"key":"B30","doi-asserted-by":"publisher","first-page":"172","DOI":"10.2174\/1574887118666230428114349","article-title":"Metformin: a promising radiosensitizer in neoadjuvant rectal cancer treatment","volume":"18","author":"Georgopoulos","year":"2023","journal-title":"Rev. Recent Clin. Trials"},{"key":"B31","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1186\/s12885-023-10530-0","article-title":"Saroglitazar suppresses the hepatocellular carcinoma induced by intraperitoneal injection of diethylnitrosamine in C57BL\/6 mice fed on choline deficient, l-amino acid-defined, high-fat diet","volume":"23","author":"Giri","year":"2023","journal-title":"BMC Cancer"},{"key":"B32","doi-asserted-by":"publisher","first-page":"577","DOI":"10.1002\/mc.23516","article-title":"Inhibition of lysophosphatidic acid receptor 6 upregulated by the choline-deficient l-amino acid-defined diet prevents hepatocarcinogenesis in mice","volume":"62","author":"Gnocchi","year":"2023","journal-title":"Mol. Carcinog."},{"key":"B33","doi-asserted-by":"publisher","first-page":"903","DOI":"10.3390\/cancers14040903","article-title":"Combination of tipifarnib and sunitinib overcomes renal cell carcinoma resistance to tyrosine kinase inhibitors via tumor-derived exosome and T cell modulation","volume":"14","author":"Greenberg","year":"2022","journal-title":"Cancers (Basel)"},{"key":"B34","doi-asserted-by":"publisher","first-page":"1289","DOI":"10.1016\/j.cell.2018.09.053","article-title":"Obesity drives STAT-1-dependent NASH and STAT-3-dependent HCC","volume":"175","author":"Grohmann","year":"2018","journal-title":"Cell"},{"key":"B35","doi-asserted-by":"publisher","first-page":"e2300706120","DOI":"10.1073\/pnas.2300706120","article-title":"Angiotensin II receptor inhibition ameliorates liver fibrosis and enhances hepatocellular carcinoma infiltration by effector T cells","volume":"120","author":"Gu","year":"2023","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"B36","doi-asserted-by":"publisher","first-page":"05080","DOI":"10.1016\/j.jhep.2023.08.026","article-title":"99% of patients with NAFLD meet MASLD criteria and natural history is therefore identical","volume":"2023","author":"Hagstr\u00f6m","year":"2023","journal-title":"J. Hepatol."},{"key":"B37","doi-asserted-by":"publisher","first-page":"451","DOI":"10.1146\/annurev-pathol-012615-044224","article-title":"Nonalcoholic fatty liver disease: pathogenesis and disease spectrum","volume":"11","author":"Hardy","year":"2016","journal-title":"Annu. Rev. Pathol."},{"key":"B38","doi-asserted-by":"publisher","first-page":"e0277","DOI":"10.1097\/HC9.0000000000000277","article-title":"Loss of KDM6B epigenetically confers resistance to lipotoxicity in nonalcoholic fatty liver disease-related HCC","volume":"7","author":"Hatano","year":"2023","journal-title":"Hepatol. Commun."},{"key":"B39","doi-asserted-by":"publisher","first-page":"05164","DOI":"10.1016\/j.jhep.2023.09.035","article-title":"Changing from NAFLD to MASLD: the new definition can more accurately identify individuals at higher risk for diabetes","author":"He","year":"2023","journal-title":"J. Hepatol."},{"key":"B40","doi-asserted-by":"publisher","first-page":"760860","DOI":"10.3389\/fendo.2021.760860","article-title":"Emerging roles of T cells in the pathogenesis of nonalcoholic steatohepatitis and hepatocellular carcinoma","volume":"12","author":"Hirsova","year":"2021","journal-title":"Front. Endocrinol. (Lausanne)"},{"key":"B41","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1093\/carcin\/bgx112","article-title":"Eicosapentaenoic acid attenuates obesity-related hepatocellular carcinogenesis","volume":"39","author":"Inoue-Yamauchi","year":"2018","journal-title":"Carcinogenesis"},{"key":"B42","doi-asserted-by":"publisher","first-page":"1476","DOI":"10.1016\/j.jhep.2021.08.012","article-title":"Epidemiology and risk-stratification of NAFLD-associated HCC","volume":"75","author":"Ioannou","year":"2021","journal-title":"J. Hepatol."},{"key":"B43","doi-asserted-by":"publisher","first-page":"1304","DOI":"10.1158\/1940-6207.CAPR-13-0178","article-title":"Lycopene metabolite, apo-10'-lycopenoic acid, inhibits diethylnitrosamine-initiated, high fat diet-promoted hepatic inflammation and tumorigenesis in mice","volume":"6","author":"Ip","year":"2013","journal-title":"Cancer Prev. Res. (Phila)"},{"key":"B44","doi-asserted-by":"publisher","first-page":"1219","DOI":"10.1158\/1940-6207.CAPR-14-0154","article-title":"Lycopene attenuated hepatic tumorigenesis via differential mechanisms depending on carotenoid cleavage enzyme in mice","volume":"7","author":"Ip","year":"2014","journal-title":"Cancer Prev. Res. (Phila)"},{"key":"B45","doi-asserted-by":"publisher","first-page":"863756","DOI":"10.3389\/fphar.2022.863756","article-title":"Scoparone improves nonalcoholic steatohepatitis through alleviating JNK\/sab signaling pathway-mediated mitochondrial dysfunction","volume":"13","author":"Jiang","year":"2022","journal-title":"Front. Pharmacol."},{"key":"B46","doi-asserted-by":"publisher","first-page":"00914","DOI":"10.1016\/j.cgh.2023.11.003","article-title":"Prevalence of steatotic liver disease (MASLD, MetALD, and ALD) in the United States: NHANES 2017-2020","author":"Kalligeros","year":"2023","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"B47","doi-asserted-by":"publisher","first-page":"121185","DOI":"10.1016\/j.lfs.2022.121185","article-title":"Shedding light on non-alcoholic fatty liver disease: pathogenesis, molecular mechanisms, models, and emerging therapeutics","volume":"312","author":"Khairnar","year":"2023","journal-title":"LIFE Sci."},{"key":"B48","doi-asserted-by":"publisher","first-page":"101213","DOI":"10.1016\/j.jceh.2023.06.013","article-title":"NAFLD and NAFLD-related HCC in asia: burden and surveillance","volume":"14","author":"Koh","year":"2024","journal-title":"J. Clin. Exp. Hepatol."},{"key":"B49","doi-asserted-by":"publisher","first-page":"5722","DOI":"10.3390\/ijms21165722","article-title":"Glucagon-like peptide-1 receptor agonist prevented the progression of hepatocellular carcinoma in a mouse model of nonalcoholic steatohepatitis","volume":"21","author":"Kojima","year":"2020","journal-title":"Int. J. Mol. Sci."},{"key":"B50","doi-asserted-by":"publisher","first-page":"1129","DOI":"10.3389\/fphar.2019.01129","article-title":"Cyclophilin inhibitor NV556 reduces fibrosis and hepatocellular carcinoma development in mice with non-alcoholic steatohepatitis","volume":"10","author":"Kuo","year":"2019","journal-title":"Front. Pharmacol."},{"key":"B51","doi-asserted-by":"publisher","first-page":"2184991","DOI":"10.1080\/2162402X.2023.2184991","article-title":"Anti-CD122 antibody restores specific CD8(+) T cell response in nonalcoholic steatohepatitis and prevents hepatocellular carcinoma growth","volume":"12","author":"Lacotte","year":"2023","journal-title":"Oncoimmunology"},{"key":"B52","doi-asserted-by":"publisher","first-page":"1164","DOI":"10.4251\/wjgo.v13.i9.1164","article-title":"Scoparone inhibits pancreatic cancer through PI3K\/Akt signaling pathway","volume":"13","author":"Li","year":"2021","journal-title":"World J. Gastrointest. Oncol."},{"key":"B53","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1007\/s11605-018-4004-6","article-title":"Pioglitazone reduces hepatocellular carcinoma development in two rodent models of cirrhosis","volume":"23","author":"Li","year":"2019","journal-title":"J. Gastrointest. Surg."},{"key":"B54","doi-asserted-by":"publisher","first-page":"1047570","DOI":"10.3389\/fimmu.2022.1047570","article-title":"Akkermansia muciniphila suppressing nonalcoholic steatohepatitis associated tumorigenesis through CXCR6(+) natural killer T cells","volume":"13","author":"Li","year":"2022","journal-title":"Front. Immunol."},{"key":"B55","doi-asserted-by":"publisher","first-page":"2040622319872118","DOI":"10.1177\/2040622319872118","article-title":"n-3 PUFAs reduce tumor load and improve survival in a NASH-tumor mouse model","volume":"10","author":"Liebig","year":"2019","journal-title":"Ther. Adv. Chronic Dis."},{"key":"B56","doi-asserted-by":"publisher","first-page":"500","DOI":"10.1016\/j.tem.2021.04.008","article-title":"Links between metabolic syndrome and metabolic dysfunction-associated fatty liver disease","volume":"32","author":"Lim","year":"2021","journal-title":"Trends Endocrinol. metabolism TEM"},{"key":"B57","doi-asserted-by":"publisher","first-page":"e22391","DOI":"10.1002\/jbt.22391","article-title":"ATGL promotes the proliferation of hepatocellular carcinoma cells via the p-AKT signaling pathway","volume":"33","author":"Liu","year":"2019","journal-title":"J. Biochem. Mol. Toxicol."},{"key":"B58","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1038\/s41572-020-00240-3","article-title":"Hepatocellular carcinoma","volume":"7","author":"Llovet","year":"2021","journal-title":"Nat. Rev. Dis. Prim."},{"key":"B59","first-page":"2668","article-title":"Berberine prevents non-alcoholic steatohepatitis-derived hepatocellular carcinoma by inhibiting inflammation and angiogenesis in mice","volume":"11","author":"Luo","year":"2019","journal-title":"Am. J. Transl. Res."},{"key":"B60","doi-asserted-by":"publisher","first-page":"641","DOI":"10.1038\/s41591-019-0379-5","article-title":"Platelet GPIb\u03b1 is a mediator and potential interventional target for NASH and subsequent liver cancer","volume":"25","author":"Malehmir","year":"2019","journal-title":"Nat. Med."},{"key":"B61","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1146\/annurev-med-090514-013832","article-title":"Liver cancer: connections with obesity, fatty liver, and cirrhosis","volume":"67","author":"Marengo","year":"2016","journal-title":"Annu. Rev. Med."},{"key":"B62","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1111\/liv.13031","article-title":"The story of HCC in NAFLD: from epidemiology, across pathogenesis, to prevention and treatment","volume":"36","author":"Margini","year":"2016","journal-title":"Liver Int."},{"key":"B63","doi-asserted-by":"publisher","first-page":"9547613","DOI":"10.1155\/2018\/9547613","article-title":"Role of oxidative stress in pathophysiology of nonalcoholic fatty liver disease","volume":"2018","author":"Masarone","year":"2018","journal-title":"Oxid. Med. Cell Longev."},{"key":"B64","doi-asserted-by":"publisher","first-page":"594","DOI":"10.1016\/j.cgh.2014.08.013","article-title":"Temporal trends of nonalcoholic fatty liver disease-related hepatocellular carcinoma in the veteran affairs population","volume":"13","author":"Mittal","year":"2015","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"B65","doi-asserted-by":"publisher","first-page":"771","DOI":"10.1111\/cas.13902","article-title":"Ezetimibe suppresses development of liver tumors by inhibiting angiogenesis in mice fed a high-fat diet","volume":"110","author":"Miura","year":"2019","journal-title":"Cancer Sci."},{"key":"B66","doi-asserted-by":"publisher","first-page":"41","DOI":"10.2174\/1389450124666221104094918","article-title":"Metformin: a promising antidiabetic medication for cancer treatment","volume":"24","author":"Mu","year":"2023","journal-title":"Curr. Drug Targets"},{"key":"B67","doi-asserted-by":"publisher","first-page":"1242","DOI":"10.1002\/hep.31157","article-title":"Risk of cirrhosis and hepatocellular cancer in patients with NAFLD and normal liver enzymes","volume":"72","author":"Natarajan","year":"2020","journal-title":"Hepatology"},{"key":"B68","first-page":"00833","article-title":"Embracing change: from NAFLD to MASLD under the steatotic liver disease umbrella","author":"Noureddin","year":"2023","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"B69","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1038\/nrgastro.2016.169","article-title":"The intestinal epithelial barrier: a therapeutic target","volume":"14","author":"Odenwald","year":"2017","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"B70","doi-asserted-by":"publisher","first-page":"1515","DOI":"10.3390\/cancers13071515","article-title":"Honokiol prevents non-alcoholic steatohepatitis-induced liver cancer via EGFR degradation through the glucocorticoid receptor-MIG6 Axis","volume":"13","author":"Okuda","year":"2021","journal-title":"Cancers (Basel)"},{"key":"B71","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1093\/oncolo\/oyac251","article-title":"Resection of NAFLD\/NASH-related hepatocellular carcinoma (HCC): clinical features and outcomes compared with HCC due to other etiologies","volume":"28","author":"Pal Chaudhary","year":"2023","journal-title":"Oncologist"},{"key":"B72","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1016\/j.cell.2009.12.052","article-title":"Dietary and genetic obesity promote liver inflammation and tumorigenesis by enhancing IL-6 and TNF expression","volume":"140","author":"Park","year":"2010","journal-title":"Cell"},{"key":"B73","doi-asserted-by":"publisher","first-page":"46","DOI":"10.3390\/children4060046","article-title":"The role of lipid and lipoprotein metabolism in non-alcoholic fatty liver disease","volume":"4","author":"Perla","year":"2017","journal-title":"Child. (Basel, Switz."},{"key":"B74","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1097\/MOL.0000000000000814","article-title":"Metabolic dysfunction-associated fatty liver disease: advances in genetic and epigenetic implications","volume":"33","author":"Pirola","year":"2022","journal-title":"Curr. Opin. Lipidol."},{"key":"B75","doi-asserted-by":"publisher","first-page":"827","DOI":"10.1002\/hep.28368","article-title":"Clinical patterns of hepatocellular carcinoma in nonalcoholic fatty liver disease: a multicenter prospective study","volume":"63","author":"Piscaglia","year":"2016","journal-title":"Hepatology"},{"key":"B76","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1016\/j.semcancer.2023.04.010","article-title":"Nonalcoholic fatty liver disease and hepatocellular carcinoma:Insights in epidemiology, pathogenesis, imaging, prevention and therapy","volume":"93","author":"Polyzos","year":"2023","journal-title":"Semin. Cancer Biol."},{"key":"B77","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1002\/hep.30036","article-title":"Hepatocellular carcinoma is associated with gut microbiota profile and inflammation in nonalcoholic fatty liver disease","volume":"69","author":"Ponziani","year":"2019","journal-title":"Hepatology"},{"key":"B78","doi-asserted-by":"publisher","first-page":"3002","DOI":"10.1111\/jgh.15631","article-title":"Circulating tumor necrosis factor-\u03b1 levels in non-alcoholic fatty liver disease: a systematic review and a meta-analysis","volume":"36","author":"Potoupni","year":"2021","journal-title":"J. Gastroenterol. Hepatol."},{"key":"B79","doi-asserted-by":"publisher","first-page":"2212","DOI":"10.1016\/S0140-6736(20)32511-3","article-title":"Non-alcoholic fatty liver disease","volume":"397","author":"Powell","year":"2021","journal-title":"Lancet"},{"key":"B80","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1016\/j.canlet.2018.01.064","article-title":"Inhibition of dipeptidyl peptidase IV prevents high fat diet-induced liver cancer angiogenesis by downregulating chemokine ligand 2","volume":"420","author":"Qin","year":"2018","journal-title":"Cancer Lett."},{"key":"B81","doi-asserted-by":"publisher","first-page":"1294267","DOI":"10.3389\/fmed.2023.1294267","article-title":"Unmasking the enigma of lipid metabolism in metabolic dysfunction-associated steatotic liver disease: from mechanism to the clinic","volume":"10","author":"Rao","year":"2023","journal-title":"Front. Med. (Lausanne)."},{"key":"B82","doi-asserted-by":"publisher","first-page":"949603","DOI":"10.3389\/fcell.2022.949603","article-title":"Fine-tuning of regulatory T cells is indispensable for the metabolic steatosis-related hepatocellular carcinoma: a review","volume":"10","author":"Riaz","year":"2022","journal-title":"Front. Cell Dev. Biol."},{"key":"B83","doi-asserted-by":"publisher","first-page":"1966","DOI":"10.1097\/hep.0000000000000520","article-title":"A multi-society Delphi consensus statement on new fatty liver disease nomenclature","author":"Rinella","year":"","journal-title":"J. Hepatol."},{"key":"B84","doi-asserted-by":"publisher","first-page":"101133","DOI":"10.1016\/j.aohep.2023.101133","article-title":"A multi-society Delphi consensus statement on new fatty liver disease nomenclature","volume":"29","author":"Rinella","year":"","journal-title":"Ann. Hepatol."},{"key":"B85","doi-asserted-by":"publisher","first-page":"1542","DOI":"10.1016\/j.jhep.2023.06.003","article-title":"A multi-society Delphi consensus statement on new fatty liver disease nomenclature","volume":"79","author":"Rinella","year":"","journal-title":"Hepatology"},{"key":"B86","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1038\/s43018-020-00168-3","article-title":"LXR\u03b1 activation and Raf inhibition trigger lethal lipotoxicity in liver cancer","volume":"2","author":"Rudalska","year":"2021","journal-title":"Nat. Cancer"},{"key":"B87","doi-asserted-by":"publisher","first-page":"5913","DOI":"10.21873\/anticanres.15410","article-title":"Repurposing metformin for cancer treatment: a great challenge of a promising drug","volume":"41","author":"Saengboonmee","year":"2021","journal-title":"Anticancer Res."},{"key":"B88","doi-asserted-by":"publisher","first-page":"2267","DOI":"10.1016\/S0140-6736(10)60408-4","article-title":"Lipid-induced insulin resistance: unravelling the mechanism","volume":"375","author":"Samuel","year":"2010","journal-title":"Lancet"},{"key":"B89","doi-asserted-by":"publisher","first-page":"869","DOI":"10.1007\/s13105-023-00954-4","article-title":"Metabolic dysfunction-associated fatty liver disease (MAFLD): an update of the recent advances in pharmacological treatment","volume":"79","author":"Sangro","year":"2023","journal-title":"J. Physiol. Biochem."},{"key":"B90","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1016\/S2468-1253(19)30342-5","article-title":"Liver diseases in the asia-pacific region: a lancet gastroenterology and hepatology commission","volume":"5","author":"Sarin","year":"2020","journal-title":"Lancet Gastroenterol. Hepatol."},{"key":"B91","doi-asserted-by":"publisher","first-page":"952","DOI":"10.1016\/j.freeradbiomed.2013.08.174","article-title":"Free radical biology for medicine: learning from nonalcoholic fatty liver disease","volume":"65","author":"Serviddio","year":"2013","journal-title":"Free Radic. Biol. Med."},{"key":"B92","doi-asserted-by":"publisher","first-page":"340","DOI":"10.1038\/nature24302","article-title":"Inflammation-induced IgA+ cells dismantle anti-liver cancer immunity","volume":"551","author":"Shalapour","year":"2017","journal-title":"Nature"},{"key":"B93","doi-asserted-by":"publisher","first-page":"105627","DOI":"10.1016\/j.tiv.2023.105627","article-title":"Scoparone induces both apoptosis and ferroptosis via multiple mechanisms in non-small-cell lung cancer cells","volume":"91","author":"Shen","year":"2023","journal-title":"Toxicol Vitro"},{"key":"B94","doi-asserted-by":"publisher","first-page":"105546","DOI":"10.1016\/j.oraloncology.2021.105546","article-title":"Tipifarnib enhances anti-EGFR activity of cetuximab in non-HRas mutated head and neck squamous cell carcinoma cancer (HNSCC)","volume":"122","author":"Shu","year":"2021","journal-title":"Oral Oncol."},{"key":"B95","doi-asserted-by":"publisher","first-page":"3252","DOI":"10.1158\/0008-5472.CAN-23-0282","article-title":"Tipifarnib potentiates the antitumor effects of PI3K\u03b1 inhibition in PIK3CA- and HRAS-dysregulated HNSCC via convergent inhibition of mTOR activity","volume":"83","author":"Smith","year":"2023","journal-title":"Cancer Res."},{"key":"B96","doi-asserted-by":"publisher","first-page":"1352","DOI":"10.1016\/j.jhep.2023.07.005","article-title":"Bifidobacterium pseudolongum-generated acetate suppresses non-alcoholic fatty liver disease-associated hepatocellular carcinoma","author":"Song","year":"2023","journal-title":"J. Hepatol."},{"key":"B97","doi-asserted-by":"publisher","first-page":"e00131","DOI":"10.14309\/ctg.0000000000000131","article-title":"Altered microbiota diversity and bile acid signaling in cirrhotic and noncirrhotic NASH-HCC","volume":"11","author":"Sydor","year":"2020","journal-title":"Clin. Transl. Gastroenterol."},{"key":"B98","doi-asserted-by":"publisher","first-page":"E987","DOI":"10.1152\/ajpendo.00133.2013","article-title":"Metformin prevents liver tumorigenesis induced by high-fat diet in C57Bl\/6 mice","volume":"305","author":"Tajima","year":"2013","journal-title":"Am. J. Physiol. Endocrinol. Metab."},{"key":"B99","doi-asserted-by":"publisher","first-page":"100811","DOI":"10.1016\/j.jhepr.2023.100811","article-title":"Non-alcoholic fatty liver disease and diabetes mellitus as growing aetiologies of hepatocellular carcinoma","volume":"5","author":"Talamantes","year":"2023","journal-title":"JHEP Rep."},{"key":"B100","doi-asserted-by":"publisher","first-page":"1249","DOI":"10.1007\/s00535-012-0739-0","article-title":"Increased hepatic oxidative DNA damage in patients with nonalcoholic steatohepatitis who develop hepatocellular carcinoma","volume":"48","author":"Tanaka","year":"2013","journal-title":"J. Gastroenterol."},{"key":"B101","doi-asserted-by":"publisher","first-page":"4642","DOI":"10.1158\/0008-5472.CAN-17-1925","article-title":"Tipifarnib inhibits HRAS-driven dedifferentiated thyroid cancers","volume":"78","author":"Untch","year":"2018","journal-title":"Cancer Res."},{"key":"B102","doi-asserted-by":"publisher","first-page":"1887","DOI":"10.1016\/j.ajpath.2023.08.007","article-title":"The role of endoplasmic reticulum in lipotoxicity during metabolic dysfunction-associated steatotic liver disease (MASLD) pathogenesis","volume":"193","author":"Venkatesan","year":"2023","journal-title":"Am. J. Pathol."},{"key":"B103","doi-asserted-by":"publisher","first-page":"1450","DOI":"10.1056\/NEJMra1713263","article-title":"Hepatocellular carcinoma","volume":"380","author":"Villanueva","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"B104","doi-asserted-by":"publisher","first-page":"748","DOI":"10.1016\/j.jhep.2022.03.010","article-title":"Metformin treatment rescues CD8(+) T-cell response to immune checkpoint inhibitor therapy in mice with NAFLD","volume":"77","author":"Wabitsch","year":"2022","journal-title":"J. Hepatol."},{"key":"B105","doi-asserted-by":"publisher","first-page":"4055","DOI":"10.21873\/anticanres.15902","article-title":"Oral administration of Mulberry (morus alba L.) Leaf powder prevents the development of hepatocellular carcinoma in stelic animal model (STAM) mice","volume":"42","author":"Wakame","year":"2022","journal-title":"Anticancer Res."},{"key":"B106","doi-asserted-by":"publisher","first-page":"113374","DOI":"10.1016\/j.biopha.2022.113374","article-title":"An overview of ferroptosis in non-alcoholic fatty liver disease","volume":"153","author":"Wang","year":"2022","journal-title":"Biomed. Pharmacother."},{"key":"B107","doi-asserted-by":"publisher","first-page":"910","DOI":"10.1016\/j.jhep.2021.11.031","article-title":"TAZ-induced Cybb contributes to liver tumor formation in non-alcoholic steatohepatitis","volume":"76","author":"Wang","year":"2022","journal-title":"J. Hepatol."},{"key":"B108","doi-asserted-by":"publisher","first-page":"1788","DOI":"10.1002\/ijc.24689","article-title":"Dietary lycopene and tomato extract supplementations inhibit nonalcoholic steatohepatitis-promoted hepatocarcinogenesis in rats","volume":"126","author":"Wang","year":"2010","journal-title":"Int. J. Cancer"},{"key":"B109","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1038\/s41392-023-01720-0","article-title":"Targeting epigenetic and posttranslational modifications regulating ferroptosis for the treatment of diseases","volume":"8","author":"Wang","year":"","journal-title":"Signal Transduct. Target Ther."},{"key":"B110","doi-asserted-by":"publisher","first-page":"100916","DOI":"10.1016\/j.drup.2022.100916","article-title":"Overcoming cancer chemotherapy resistance by the induction of ferroptosis","volume":"66","author":"Wang","year":"","journal-title":"Drug resist. updat."},{"key":"B111","doi-asserted-by":"publisher","first-page":"113770","DOI":"10.1016\/j.biopha.2022.113770","article-title":"The effects of scoparone on alcohol and high-fat diet-induced liver injury revealed by RNA sequencing","volume":"155","author":"Wei","year":"2022","journal-title":"Biomed. Pharmacother."},{"key":"B112","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1038\/s41423-020-00558-8","article-title":"Hepatic macrophages in liver homeostasis and diseases-diversity, plasticity and therapeutic opportunities","volume":"18","author":"Wen","year":"2021","journal-title":"Cell. Mol. Immunol."},{"key":"B113","doi-asserted-by":"publisher","first-page":"1061149","DOI":"10.1007\/978-981-10-8684-7_12","article-title":"Current prevention and treatment options for NAFLD","volume":"157","author":"Wong","year":"2018","journal-title":"Adv. Exp. Med. Biol."},{"key":"B114","doi-asserted-by":"publisher","first-page":"328","DOI":"10.3892\/etm.2023.12027","article-title":"Scoparone inhibits breast cancer cell viability through the NF-\u03baB signaling pathway","volume":"26","author":"Wu","year":"","journal-title":"Exp. Ther. Med."},{"key":"B115","doi-asserted-by":"publisher","first-page":"16931","DOI":"10.1007\/s00432-023-05391-w","article-title":"Current status and frontier tracking of clinical trials on Metformin for cancer treatment","volume":"149","author":"Wu","year":"","journal-title":"J. Cancer Res. Clin. Oncol."},{"key":"B116","doi-asserted-by":"publisher","first-page":"797","DOI":"10.1158\/1940-6207.CAPR-18-0188","article-title":"Dietary tomato powder inhibits high-fat diet-promoted hepatocellular carcinoma with alteration of gut microbiota in mice lacking carotenoid cleavage enzymes","volume":"11","author":"Xia","year":"2018","journal-title":"Cancer Prev. Res. (Phila)"},{"key":"B117","doi-asserted-by":"publisher","first-page":"19355","DOI":"10.18632\/oncotarget.8466","article-title":"Distinctly altered gut microbiota in the progression of liver disease","volume":"7","author":"Xie","year":"2016","journal-title":"Oncotarget"},{"key":"B118","doi-asserted-by":"publisher","DOI":"10.1007\/s11010-023-04893-y","article-title":"Ferroptosis: a new promising target for hepatocellular carcinoma therapy","author":"Xu","year":"2023","journal-title":"Mol. Cell. Biochem."},{"key":"B119","doi-asserted-by":"publisher","first-page":"538","DOI":"10.1016\/j.jhep.2023.02.033","article-title":"Role of immune responses in the development of NAFLD-associated liver cancer and prospects for therapeutic modulation","volume":"79","author":"Yahoo","year":"2023","journal-title":"J. Hepatol."},{"key":"B120","doi-asserted-by":"publisher","first-page":"11546","DOI":"10.3390\/ijms241411546","article-title":"Suppression of NASH-related HCC by farnesyltransferase inhibitor through inhibition of inflammation and hypoxia-inducible factor-1\u03b1 expression","volume":"24","author":"Yamada","year":"","journal-title":"Int. J. Mol. Sci."},{"key":"B121","doi-asserted-by":"publisher","first-page":"66","DOI":"10.2152\/jmi.70.66","article-title":"Effect of daikenchuto (TU-100) on carcinogenesis in non-alcoholic steatohepatitis","volume":"70","author":"Yamada","year":"","journal-title":"J. Med. Invest."},{"key":"B122","doi-asserted-by":"publisher","first-page":"05161","DOI":"10.1016\/j.jhep.2023.09.033","article-title":"Transitioning from NAFLD to MAFLD and MASLD: consistent prevalence and risk factors in a Chinese cohort","author":"Yang","year":"","journal-title":"J. Hepatol."},{"key":"B123","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1002\/path.6065","article-title":"TUBB4B is a novel therapeutic target in non-alcoholic fatty liver disease-associated hepatocellular carcinoma","volume":"260","author":"Yang","year":"","journal-title":"J. Pathol."},{"key":"B124","doi-asserted-by":"publisher","DOI":"10.1002\/tox.23851","article-title":"Scoparone inhibits the development of hepatocellular carcinoma by modulating the p38 MAPK\/Akt\/NF-\u03baB signaling in nonalcoholic fatty liver disease mice","author":"Ye","year":"2023","journal-title":"Environ. Toxicol."},{"key":"B125","doi-asserted-by":"publisher","first-page":"114861","DOI":"10.1016\/j.ejmech.2022.114861","article-title":"Ferroptosis-related small-molecule compounds in cancer therapy: strategies and applications","volume":"244","author":"Yin","year":"2022","journal-title":"Eur. J. Med. Chem."},{"key":"B126","doi-asserted-by":"publisher","first-page":"1499","DOI":"10.3892\/ijmm.2016.2766","article-title":"Rosuvastatin as a potential preventive drug for the development of hepatocellular carcinoma associated with non-alcoholic fatty liver disease in mice","volume":"38","author":"Yokohama","year":"2016","journal-title":"Int. J. Mol. Med."},{"key":"B127","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1038\/nrgastro.2017.109","article-title":"Global burden of NAFLD and NASH: trends, predictions, risk factors and prevention","volume":"15","author":"Younossi","year":"2018","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"B128","doi-asserted-by":"publisher","first-page":"1723","DOI":"10.1002\/hep.28123","article-title":"Association of nonalcoholic fatty liver disease (NAFLD) with hepatocellular carcinoma (HCC) in the United States from 2004 to 2009","volume":"62","author":"Younossi","year":"2015","journal-title":"Hepatology"},{"key":"B129","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1016\/j.semcancer.2013.07.003","article-title":"Obesity, insulin resistance, NASH and hepatocellular carcinoma","volume":"23","author":"Yu","year":"2013","journal-title":"Semin. Cancer Biol."},{"key":"B130","doi-asserted-by":"publisher","first-page":"358","DOI":"10.1002\/path.5530","article-title":"ZHX2 inhibits SREBP1c-mediated de novo lipogenesis in hepatocellular carcinoma via miR-24-3p","volume":"252","author":"Yu","year":"2020","journal-title":"J. Pathol."},{"key":"B131","doi-asserted-by":"publisher","first-page":"789859","DOI":"10.3389\/fmed.2021.789859","article-title":"Targeting T cell subtypes for NAFLD and NAFLD-related HCC treatment: an opinion","volume":"8","author":"Zhang","year":"2021","journal-title":"Front. Med. (Lausanne)"},{"key":"B132","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1007\/s13577-022-00820-3","article-title":"TRIM59 promotes steatosis and ferroptosis in non-alcoholic fatty liver disease via enhancing GPX4 ubiquitination","volume":"36","author":"Zhang","year":"","journal-title":"Hum. Cell."},{"key":"B133","doi-asserted-by":"publisher","first-page":"154589","DOI":"10.1016\/j.phymed.2022.154589","article-title":"Phytochemical gallic acid alleviates nonalcoholic fatty liver disease via AMPK-ACC-PPARa axis through dual regulation of lipid metabolism and mitochondrial function","volume":"109","author":"Zhang","year":"","journal-title":"Phytomedicine"},{"key":"B134","doi-asserted-by":"publisher","first-page":"761","DOI":"10.1136\/gutjnl-2019-319664","article-title":"Dietary cholesterol drives fatty liver-associated liver cancer by modulating gut microbiota and metabolites","volume":"70","author":"Zhang","year":"","journal-title":"Gut"},{"key":"B135","doi-asserted-by":"publisher","first-page":"5551","DOI":"10.2147\/JIR.S330499","article-title":"Curcumae ameliorates diethylnitrosamine-induced hepatocellular carcinoma via alteration of oxidative stress, inflammation and gut microbiota","volume":"14","author":"Zhang","year":"","journal-title":"J. Inflamm. Res."},{"key":"B136","doi-asserted-by":"publisher","first-page":"11795549231188225","DOI":"10.1177\/11795549231188225","article-title":"Potential ability of probiotics in the prevention and treatment of colorectal cancer","volume":"17","author":"Zhao","year":"2023","journal-title":"Clin. Med. Insights-Oncology"},{"key":"B137","doi-asserted-by":"publisher","first-page":"1119","DOI":"10.1002\/hep.30702","article-title":"Unexpected rapid increase in the burden of NAFLD in China from 2008 to 2018: a systematic review and meta-analysis","volume":"70","author":"Zhou","year":"2019","journal-title":"Hepatology"},{"key":"B138","doi-asserted-by":"publisher","DOI":"10.1002\/tox.23882","article-title":"Scoparone attenuates glioma progression and improves the toxicity of temozolomide by suppressing RhoA\/ROCK1 signaling","author":"Zhou","year":"2023","journal-title":"Environ. Toxicol."},{"key":"B139","doi-asserted-by":"publisher","first-page":"612","DOI":"10.24976\/Discov.Med.202335177.60","article-title":"FMO1 promotes nonalcoholic fatty liver disease progression by regulating PPAR\u03b1 activation and inducing ferroptosis","volume":"35","author":"Zou","year":"2023","journal-title":"Discov. Med."}],"container-title":["Frontiers in Pharmacology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2023.1336216\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,1,18]],"date-time":"2024-01-18T23:49:35Z","timestamp":1705621775000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2023.1336216\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,1,19]]},"references-count":139,"alternative-id":["10.3389\/fphar.2023.1336216"],"URL":"https:\/\/doi.org\/10.3389\/fphar.2023.1336216","relation":{},"ISSN":["1663-9812"],"issn-type":[{"value":"1663-9812","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,1,19]]},"article-number":"1336216"}}